Knowles M - Search Results

1

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Neuzillet Y, et al. Among authors: knowles m. Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461579 French. No abstract available.

2

High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization.

Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. Hurst CD, et al. Oncogene. 2004 Mar 18;23(12):2250-63. doi: 10.1038/sj.onc.1207260. Oncogene. 2004. PMID: 14968109

3

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. Jebar AH, et al. Oncogene. 2005 Aug 4;24(33):5218-25. doi: 10.1038/sj.onc.1208705. Oncogene. 2005. PMID: 15897885

4

Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.

Tomlinson DC, L'Hôte CG, Kennedy W, Pitt E, Knowles MA. Tomlinson DC, et al. Cancer Res. 2005 Nov 15;65(22):10441-9. doi: 10.1158/0008-5472.CAN-05-1718. Cancer Res. 2005. PMID: 16288035

5

DBC1 re-expression alters the expression of multiple components of the plasminogen pathway.

Louhelainen JP, Hurst CD, Pitt E, Nishiyama H, Pickett HA, Knowles MA. Louhelainen JP, et al. Among authors: knowles ma. Oncogene. 2006 Apr 13;25(16):2409-19. doi: 10.1038/sj.onc.1209228. Oncogene. 2006. PMID: 16369496

6

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.

Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Chapman EJ, et al. Among authors: knowles ma. Oncogene. 2006 Aug 17;25(36):5037-45. doi: 10.1038/sj.onc.1209513. Epub 2006 Apr 17. Oncogene. 2006. PMID: 16619045

7

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Tomlinson DC, Hurst CD, Knowles MA. Tomlinson DC, et al. Among authors: knowles ma. Oncogene. 2007 Aug 30;26(40):5889-99. doi: 10.1038/sj.onc.1210399. Epub 2007 Mar 26. Oncogene. 2007. PMID: 17384684 Free PMC article.

8

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

Tomlinson DC, Baldo O, Harnden P, Knowles MA. Tomlinson DC, et al. Among authors: knowles ma. J Pathol. 2007 Sep;213(1):91-8. doi: 10.1002/path.2207. J Pathol. 2007. PMID: 17668422 Free PMC article.

9

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Hurst CD, et al. Among authors: knowles ma. Oncogene. 2008 Apr 24;27(19):2716-27. doi: 10.1038/sj.onc.1210934. Epub 2007 Nov 26. Oncogene. 2008. PMID: 18037967 Free PMC article.

10

Genomics: a preview of genomic medicine.

Karam JA, Shariat SF, Hsieh JT, Knowles MA. Karam JA, et al. BJU Int. 2008 Nov;102(9 Pt B):1221-7. doi: 10.1111/j.1464-410X.2008.07963.x. BJU Int. 2008. PMID: 19035885 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

805 results

Search Page